Patient Education Can Prevent Nocebo Effect With Adalimumab Biosimilars, Explains Laura Wingate

As Humira biosimilars enter the market, patient education about biosimilars is crucial to prevent the nocebo effect when patients switch from the reference product, explained Laura Wingate, executive vice president, Education, Support, & Advocacy, Crohn’s & Colitis Foundation.

Read the full article here

Related Articles